The grass-roots campaign group Science is Vital (http:// scienceisvital.org.uk) shares the Royal Society president's concerns over aspects of the government's Higher Education and Research Bill (see V. Ramakrishnan Nature 538, 459; 2016) .
The bill does not yet offer sufficient protection for the operational autonomy of the UK research councils. Neither does it provide legal guarantees that future reforms will take into account the views of Parliament or the research community.
We are also alarmed by mechanisms the bill could use to aid entry and exit of institutions from the higher-education 'market' . For example, the new Office for Students will have the power to revoke university status without parliamentary assent. Such powers undermine support for the autonomy of seats of learning and enquiry that have proved their cultural worth for generations.
In our view, verbal assurances from the Minister for Universities and Science are insufficient. The stated "primacy of scientific and academic decision-making" must be enshrined in the bill.
As the bill is readied for its third reading before being debated in the House of Lords, we call on the UK research community to contact their MPs urgently to relay concerns about the dangers in this proposed legislation (see go.nature.com/2fsmclc For universities with a royal charter, the UK government's proposed Higher Education and Research Bill does not "rip up an 800-year-old settlement" (Nature 538, 5; 2016). And on a factual point, the University of Cambridge does not have a royal charter. Pope John XXII gave us formal recognition in 1318, and our privileges were confirmed by Parliament in 1571 through the Oxford and Cambridge Act.
A royal charter recognizes an institution or group of
Precision oncology is not an illusion
In our view, it is unreasonable to condemn personalized medicine for oncology on the basis of the limited success of a few trials (see V. Prasad Nature 537, S63; 2016). We suspect that those failures were more likely to be caused by shortcomings in methodology.
With more than 40 precisiononcology drugs on the market, such therapies are helping tens of thousands of US patients by targeting specific molecular abnormalities. For example, mutations in the gene that encodes the epidermal growthfactor receptor are likely to occur in 10% of the 186,240 or so new cases of non-small-cell lung cancer predicted for 2016 (see go.nature.com/2fpxits). And the 8,220 people with chronic myeloid leukaemia (CML) predicted for this year will almost all carry the 'Philadelphia' chromosomal translocation (see go.nature.com/2fbbarj).
There are precision-oncology drugs to counteract both defects. Indeed, the life expectancy of people with CML is now starting to approach that of the general population (S. Saussele et al. Blood 126, 42-49; 2015 
Genetics boosts US-Cuban links
As economic doors open between the United States and Cuba, human genetics offers one promising area for scientific collaboration (see Nature 537, 600-603; 2016) . Reversing 50 years of restriction remains a formidable task -particularly with scant financial and human resources.
Community genetics is incorporated into Cuba's healthcare system. As in the United States, prenatal genetic testing, screening of newborns and clinical genetics services are all available. Comparative studies on US and Cuban populations could help to clarify the genetic contribution to disease -for example, by revealing rare inherited genomic variants.
Miami is one of the bestpositioned US cities to lead such scientific partnerships, given its social and cultural ties with Cuba (Florida is home to 66% of the US Cuban population UK. mjr@ast.cam.ac.uk 
